NeuClone is a clinical stage biopharmaceutical company exclusively developing and commercialising high quality biosimilar products. Led by a team of industry veterans, we are focused on creating a deep pipeline of high quality biosimilars at the scale and price to meet demand in both new and established markets globally. NeuClone is differentiated by our deep and unmatched pipeline, as well as our Right From the Start® approach where we continually confirm biosimilarity at the earliest stages and throughout development.
Looking for a particular NeuClone employee's phone or email?
NeuClone Questions
The NeuClone annual revenue was $6 million in 2026.
Glenn Pilkington is the Director of Clinical Development of NeuClone.
6 people are employed at NeuClone.
NeuClone is based in Sydney, New South Wales.
The NAICS codes for NeuClone are [5417, 541713, 54, 541, 54171].
The SIC codes for NeuClone are [87, 873].
Top NeuClone Employees
-
51
-
Glenn Pilkington
Director of Clinical Development at NeuClone
Sydney, NSW, AU25 -
Claire Tahir
Scientist I at NeuClone
Eveleigh, New South Wales, Australia1 -
Sarah Houston
Team Leader at NeuClone
Sydney, NSW, AU2 -
Gayan Jayawickrama
Senior Scientist at NeuClone
Homebush, NSW, AU1
Related Companies
